[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc purchased 1,500,000 ordinary shares under the second tranche of its buyback programme announced 31 July 2025. The shares were bought on 15 September 2025 on the London Stock Exchange/CBOE (UK)/CXE and the company intends to hold the purchased shares as treasury shares.

After settlement the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares, leaving 8,948,351,687 ordinary shares with voting rights. The announcement points investors to a full trade breakdown at the provided link and to Haleon's investor website for details.

Positive

• Executed share buyback: Purchase of 1,500,000 ordinary shares under the announced programme
• Treasury holding: Company intends to hold the purchased shares as treasury shares, preserving flexibility
• Updated capital detail: Clear post-settlement figures: 8,952,353,648 registered shares and 8,948,351,687 voting shares

Negative

• None.

Insights

Financial Analyst

TL;DR Buyback of 1.5m shares reduces outstanding voting stock and signals capital-return intent.

The transaction shows active execution of the company's previously announced share repurchase programme. Purchasing 1,500,000 shares and placing them into treasury reduces shares outstanding for dividend and voting calculations and can modestly increase per-share metrics. The filing provides precise post-settlement share counts that investors can use to update per-share calculations. No financial amounts for total spent are summarized in the body beyond per-trade prices available via the trade breakdown link.

Corporate Governance Expert

TL;DR Routine disclosure of share repurchase details and updated voting share count; governance impact is procedural.

The 6-K follows regulatory requirements by reporting transaction details and updated capital structure. Holding repurchased shares as treasury is a common approach that preserves flexibility for future use. The filing includes a link to the individual trade breakdown as required under the Market Abuse Regulation. There are no governance concerns or changes to board/executive composition disclosed in this notice.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	16 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

16 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,500,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	15 September 2025	15 September 2025	15 September 2025
Number of Shares purchased:	1,500,000	-	-
Highest price paid per Share (p):	360.6000	-	-
Lowest price paid per Share (p):	355.7000	-	-
Volume weighted average price paid per Share (p):	357.7194	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,948,351,687 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4157Z_1-2025-9-15.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 16, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLNCF) buy on 15 September 2025?

Haleon purchased 1,500,000 ordinary shares of £0.01 each on 15 September 2025 under its second buyback tranche.

How many Haleon shares are held in treasury after this transaction?

After settlement 4,001,961 shares are held as treasury shares according to the filing.

What is the number of Haleon ordinary shares with voting rights now?

The filing states there are 8,948,351,687 ordinary shares with voting rights following the purchase.

Where can I find the full breakdown of the individual trades?

A full breakdown of individual trades is available at the link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/4157Z_1-2025-9-15.pdf

Does this announcement include financial amounts spent on the buyback?

The announcement lists per-trade prices in the trade breakdown link but does not present an aggregated total spent within the main text.